ArticleRadiation oncology (London, England)2023

Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.

Mai Sakagami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.